Thirty-Two Pack-Years and a Quit Date Twelve Years Ago: A Shared Decision About Low-Dose CT Lung Cancer Screening for a 61-Year-Old Former Ironworker
[Student Name]
University of Phoenix
NRP/555: Adult and Geriatric Management I
Week 1 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. K., a 61-year-old retired ironworker, comes for his annual visit and says a friend was just diagnosed with lung cancer. He asks whether he should "get the scan." He smoked about one and a half packs a day from age 17 to 49 and quit 12 years ago. He has no cough, weight loss or other symptoms. He has hypertension and mild chronic obstructive pulmonary disease. This paper explains how I determined his eligibility and how we made the decision together.
Calculating Pack-Years
Pack-years equal packs smoked per day multiplied by years smoked. Mr. K. smoked 1.5 packs a day for 32 years, 48 pack-years. Taking an accurate smoking history matters, because people often underestimate: when I asked about years he smoked less, he recalled two years at half a pack when his daughter was born, which does not change his eligibility.
Applying the Recommendation
Under the Task Force's grade B recommendation, a yearly low-dose CT is advised for people between 50 and 80 whose smoking adds up to at least 20 pack-years, as long as they are current smokers or their last cigarette was within 15 years (U.S. Preventive Services Task Force et al., 2021). Screening should stop when a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. Mr. K. is 61, has 48 pack-years and quit 12 years ago. He is eligible, and would remain eligible for three more years unless his health changes.
The Evidence for Benefit
The National Lung Screening Trial randomly assigned more than 53,000 high-risk adults to three annual low-dose CT scans or chest radiographs and found 247 lung cancer deaths per 100,000 person-years with CT compared with 309 with radiography, a relative reduction of about 20% (National Lung Screening Trial Research Team, 2011). The NELSON trial in Europe found that among men, lung cancer mortality at 10 years was 2.50 deaths per 1,000 person-years with volume CT screening compared with 3.30 without screening, a rate ratio of 0.76 (de Koning et al., 2020).
A 20% relative reduction sounds large; the conversation needs the absolute numbers too, and the harms beside them.
The Evidence for Harm
Harms are real. In the National Lung Screening Trial, 24.2% of low-dose CT screens were positive over three rounds, and 96.4% of those positives were false positives (National Lung Screening Trial Research Team, 2011). False positives lead to more scans and sometimes biopsies, with a small risk of complications. The NELSON trial, using volume-based nodule management, had lower referral rates for suspicious nodules, 2.1% (de Koning et al., 2020). Screening also detects some cancers that would never have caused harm, called overdiagnosis, and involves low-dose radiation each year.
The Shared Decision-Making Visit
Medicare requires a counseling and shared decision-making visit before the first scan, using a decision aid and covering benefits, harms, follow-up, overdiagnosis, the importance of adherence to annual screening and smoking cessation. I use a decision aid showing, out of 1,000 people like Mr. K. screened for several years, how many avoid death from lung cancer, how many have false-positive results and how many have biopsies.
Mr. K.'s Values
Mr. K. says his priority is to catch cancer early, as his friend's was found late. He is not worried about extra scans and says he would want a biopsy if needed. His mild chronic obstructive pulmonary disease does not limit his activity, and he would accept surgery if a cancer were found. He chooses screening.
Ordering and Follow-Up
I order a baseline low-dose CT through an accredited screening program that uses standardized reporting. Results will guide the interval: most people return in 12 months, while some findings require a shorter follow-up scan or referral. I explain that the most important part of screening is returning every year.
Smoking Status
Mr. K. has not smoked for 12 years. I congratulate him and confirm that he does not use other tobacco or vape.
His Other Preventive Care
The annual visit also covers colorectal cancer screening, up to date with a colonoscopy four years ago; a one-time ultrasound for abdominal aortic aneurysm, which he will become eligible for as a former smoker at 65; blood pressure control; lipid assessment; immunizations, including pneumococcal and shingles vaccines; and hepatitis C screening, which he had previously.
What Happens After a Positive Scan
Mr. K. asked what happens if something is found. I explained that most findings are small nodules, and that standardized reporting assigns each scan a category that sets the next step: most small nodules need only a repeat scan in months to see whether they grow, while larger or suspicious ones may need a PET scan, a biopsy or referral to a pulmonologist or thoracic surgeon. Knowing the path in advance reduces anxiety when a result is not simply normal.
Incidental Findings
Low-dose CT also shows parts of the heart, upper abdomen and bones. It may reveal coronary artery calcium, emphysema, thyroid nodules or adrenal masses. Some of these findings are useful, such as calcium that informs his cardiovascular risk, while others lead to further tests of uncertain value. I told Mr. K. that I will review any incidental findings with him and recommend follow-up only when it is likely to help.
When Screening Should Stop
Because Mr. K. quit 12 years ago, he will reach 15 years without smoking at 64. Under the 2021 criteria, screening would then stop (U.S. Preventive Services Task Force et al., 2021). I noted this date in his chart so that the decision is revisited rather than continued by habit, and explained that stopping reflects his falling risk, not a lack of concern.
Why the Criteria Changed in 2021
Compared with the 2013 version, the 2021 update starts screening five years earlier and asks for 10 fewer pack-years, expanding eligibility, particularly for women and Black adults, whose lighter daily smoking had kept many below the old threshold and develop lung cancer at lower cumulative exposures. For Mr. K., either version would have made him eligible.
Cost and Access
Medicare and most private insurers cover annual screening for eligible adults without cost sharing. The nearest accredited program is 30 minutes away, and Mr. K. can drive himself.
Documentation
The note documents his pack-years, quit date, eligibility, the shared decision-making discussion with the decision aid used and his decision, which meets requirements for coverage and supports future decisions about stopping screening.
Conclusion
Mr. K., with 48 pack-years and a quit date 12 years ago, meets the 2021 Task Force criteria for annual low-dose CT screening. Trials show a meaningful reduction in lung cancer deaths, balanced by frequent false positives and some overdiagnosis. A structured shared decision-making visit allowed him to weigh those facts against his own values, and he chose to be screened, with a plan for annual follow-up and attention to his other preventive needs.
References
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., van 't Westeinde, S., Prokop, M., Mali, W. P., Mohamed Hoesein, F. A. A., van Ooijen, P. M. A., Aerts, J. G. J. V., den Bakker, M. A., Thunnissen, E., Verschakelen, J., . . . Oudkerk, M. (2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. New England Journal of Medicine, 382(6), 503-513. https://doi.org/10.1056/NEJMoa1911793
National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873
U.S. Preventive Services Task Force, Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Kubik, M., Landefeld, C. S., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C.-W., & Wong, J. B. (2021). Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(10), 962-970. https://doi.org/10.1001/jama.2021.1117
How this NRP 555 Week 1 example is structured
The NRP/555 Week 1 work usually addresses prevention and screening for adults and older adults. This paper follows one screening decision from eligibility to evidence to shared decision to follow-up, showing how a guideline becomes a conversation with a specific patient. Students search this week as NRP 555 Week 1, NRP555 Wk 1 or NRP/555 Wk 1; all three are the same assignment.
NRP/555 Week 1 questions, answered
What does NRP/555 Week 1 usually ask for?
Many sections ask students to plan preventive care and screening for an adult or older adult using current recommendations such as those of the USPSTF.
Who is eligible for lung cancer screening?
The 2021 USPSTF recommends annual low-dose CT for adults aged 50 to 80 with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years.
What are the harms of lung cancer screening?
False-positive results, which are common, follow-up scans and procedures, overdiagnosis of cancers that would not cause harm, radiation exposure and anxiety.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.